15,519 results match your criteria European Oncology & Haematology [Journal]


Triple-negative breast cancer: the reality in Chile and in Latin America.

Ecancermedicalscience 2019 22;13:893. Epub 2019 Jan 22.

Oncology Institute Arturo López Pérez Foundation, Santiago 878, Chile.

Breast cancer is the leading cause of cancer death among women worldwide. While triple-negative breast cancer is less common among various sub-types of breast cancer, it tends to affect younger women and is more aggressive, having a higher rate of early recurrence and mortality compared to other sub-types. We know about the association between triple-negative breast cancer and BRCA mutations, which are highly prevalent in founding populations of European origin, but the true prevalence of these mutations in Latin American populations is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3332/ecancer.2019.893DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6372297PMC
January 2019

Energy metabolism is co-determined by genetic variants in chronic lymphocytic leukemia and influences drug sensitivity.

Haematologica 2019 Feb 21. Epub 2019 Feb 21.

European Molecular Biology Laboratory (EMBL), Heidelberg, Germany;

Chronic lymphocytic leukemia cells have an altered energy metabolism compared to normal B cells. While there is growing understanding of the molecular heterogeneity of the disease, the extent of metabolic heterogeneity and its relation to molecular heterogeneity has not been systematically studied. Here, we assessed 11 bioenergetic features, primarily reflecting cell's oxidative phosphorylation and glycolytic activity, in leukemic cells from 140 chronic lymphocytic leukemia patients using metabolic flux analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3324/haematol.2018.203067DOI Listing
February 2019

Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study.

BMC Health Serv Res 2019 Feb 21;19(1):131. Epub 2019 Feb 21.

Syreon Research Institute, Budapest, Hungary.

Background: OnkoNetwork is a recently established integrated care model with a personalized pathway system to manage patients with first suspect of a solid tumour in secondary care, that evolved as a regional initiative in Hungary. The primary aim of OnkoNetwork is the improvement of clinical outcomes via timely access to quality assured and defragmented healthcare services. The Horizon 2020 funded SELFIE project has selected OnkoNetwork for in-depth qualitative and quantitative evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12913-019-3957-9DOI Listing
February 2019

Integrative Oncology: International Perspectives.

Integr Cancer Ther 2019 Jan-Dec;18:1534735418823266

8 Memorial Sloan Kettering Cancer Center, NY, USA.

Interest in integrative oncology (IO) is growing globally. Patients with cancer are actively using traditional complementary and integrative medicine (TCIM) as part of their cancer and survivorship care. Published studies from around the world report increasing use of TCIM by people living with cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1534735418823266DOI Listing
February 2019

Long-Term Changes of Symptoms of Anxiety, Depression, and Fatigue in Cancer Patients 6 Months After the End of Yoga Therapy.

Integr Cancer Ther 2019 Jan-Dec;18:1534735418822096

1 University Medical Center, Comprehensive Cancer Center Mainfranken, University of Würzburg, Würzburg, Germany.

Background: Symptoms of anxiety, depression, and cancer-related fatigue are commonly associated with cancer. Cancer patients increasingly use complementary and alternative treatments, such as yoga, to cope with psychological and physical impairments. In the present article, long-term changes of anxiety, depression, and fatigue in cancer are examined 6 months after a yoga intervention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1534735418822096DOI Listing
February 2019

Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ.

Br J Surg 2019 Feb 21. Epub 2019 Feb 21.

Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA.

Background: Microinvasive breast cancer is an uncommon pathological entity. Owing to the rarity of this condition, its surgical axillary management and overall prognosis remain controversial.

Methods: A database was analysed to identify patients with microinvasive ductal carcinoma in situ (DCIS) who had surgery for invasive breast cancer at the European Institute of Oncology, Milan, between 1998 and 2010. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/bjs.11079DOI Listing
February 2019

The relation of radiological tumor volume response to histological response and outcome in patients with localized Ewing Sarcoma.

Cancer Med 2019 Feb 21. Epub 2019 Feb 21.

Emma Children's Hospital, Department of Pediatric Oncology, Academic Medical Center, Amsterdam, The Netherlands.

Background: Magnetic resonance imaging (MRI) is the modality of choice for local staging and response evaluation of Ewing sarcoma (EwS). Aim of this study was to determine the relevance of tumor volume response (TVR) in relation to histological response (HisRes) and survival, in order to evaluate if early modification of chemotherapy might be indicated in patients with inadequate TVR.

Methods: Three dimensional (3D)-tumor volume data at diagnosis, during early induction phase (1-3 courses of chemotherapy; n = 195) and/or late induction phase (4-6 courses; n = 175) from 241 localized patients were retrospectively analyzed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cam4.2002DOI Listing
February 2019

PROMs following breast-conserving therapy for breast cancer: results from a prospective longitudinal monocentric study.

Support Care Cancer 2019 Feb 21. Epub 2019 Feb 21.

Department of Oncology, Experimental Radiation Oncology, KU Leuven-University of Leuven, B-3000, Leuven, Belgium.

Background: Treatment of breast cancer includes many options and shared decision making is becoming standard practice. Within the context of treatment individualization, the omission of radiotherapy (RT) can be considered. It is thereby of great importance to correctly foresee the side effects attributed to RT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04698-0DOI Listing
February 2019

A pilot study on aesthetic treatments performed by qualified aesthetic practitioners: efficacy on health-related quality of life in breast cancer patients.

Qual Life Res 2019 Feb 20. Epub 2019 Feb 20.

Department of Oncology and Hematoncology (DIPO), University of Milan, Via Festa del Perdono 7, 20122, Milan, Italy.

Purpose: Cancer treatments often produce undesirable side-effects, such as skin toxicity, impacting on everyday functioning and health-related quality of life (HRQoL). This experimental study sought to determine whether aesthetic products and treatments could significantly decrease perceived skin symptoms, psychological distress and improve skin-related QoL (SRQoL).

Methods: An experimental group composed of 100 breast patients was enrolled for specialized aesthetic treatments at the European Institute of Oncology (IEO) and compared to a control group of 70 breast patients who did not receive any aesthetic treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11136-019-02133-9DOI Listing
February 2019

Tie2 activation promotes choriocapillary regeneration for alleviating neovascular age-related macular degeneration.

Sci Adv 2019 Feb 13;5(2):eaau6732. Epub 2019 Feb 13.

Center for Vascular Research, Institute for Basic Science (IBS), Daejeon 34141, Republic of Korea.

Choriocapillary loss is a major cause of neovascular age-related macular degeneration (NV-AMD). Although vascular endothelial growth factor (VEGF) blockade for NV-AMD has shown beneficial outcomes, unmet medical needs for patients refractory or tachyphylactic to anti-VEGF therapy exist. In addition, the treatment could exacerbate choriocapillary rarefaction, necessitating advanced treatment for fundamental recovery from NV-AMD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/sciadv.aau6732DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374104PMC
February 2019

Cost-utility analysis of colonoscopy or faecal immunochemical test for population-based organised colorectal cancer screening.

United European Gastroenterol J 2019 Feb 19;7(1):105-113. Epub 2018 Sep 19.

Center for Health Technology and Services Research (CINTESIS), University of Porto (FMUP), Porto, Portugal.

Background: Organised programmes for colorectal cancer screening demand a high burden of medical and economic resources. The preferred methods are the faecal immunochemical test and primary colonoscopy.

Objective: The purpose of this study was to perform an economic analysis and comparison between these tests in Europe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050640618803196DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374854PMC
February 2019

Palliative endoscopic drainage of malignant stenosis of biliary confluence: Efficiency of multiple drainage approach to drain a maximum of liver segments.

United European Gastroenterol J 2019 Feb 27;7(1):52-59. Epub 2018 Sep 27.

Endoscopy Unit, Paoli Calmettes Institute, Marseille, France.

Background And Aim: More than 50% of the liver should be drained in case of unresectable hilar liver stenosis; however, it remains unclear if the use of several types of drainage (endoscopic retrograde cholangiography and pancreatography, percutaneous-biliary drainage, endoscopic ultrasound biliary drainage (EUS-BD)), allowing better drainage, has an impact on survival. The aim of our study was to evaluate the percentage of liver drained and its correlation on survival whatever the drainage technique used.

Patients And Methods: This study was a retrospective analysis of a prospective registry of patients with malignant drainage stenosis of the hilum. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050640618803812DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374838PMC
February 2019

Performance measures for endoscopy services: A European Society of Gastrointestinal Endoscopy (ESGE) quality improvement initiative.

United European Gastroenterol J 2019 Feb 4;7(1):21-44. Epub 2018 Nov 4.

Northern Institute for Cancer Research, Newcastle University, Newcastle, UK.

The European Society of Gastrointestinal Endoscopy (ESGE) and United European Gastroenterology present a list of key performance measures for endoscopy services. We recommend that these performance measures be adopted by all endoscopy services across Europe. The measures include those related to the leadership, organization, and delivery of the service, as well as those associated with the patient journey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2050640618810242DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374839PMC
February 2019

Identification of patients with pancreatic adenocarcinoma due to inheritable mutation: Challenges of daily clinical practice.

World J Gastrointest Oncol 2019 Feb;11(2):102-116

Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester M204BX, United Kingdom.

Background: Identification of germ-line mutations in pancreatic ductal adenocarcinoma (PDAC) could impact on patient/family.

Aim: To assess the referral pathways for genetic consultations in PDAC.

Methods: Electronic records of PDAC patients were reviewed retrospectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4251/wjgo.v11.i2.102DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379756PMC
February 2019

Genome-wide association study of germline variants and breast cancer-specific mortality.

Authors:
Maria Escala-Garcia Qi Guo Thilo Dörk Sander Canisius Renske Keeman Joe Dennis Jonathan Beesley Julie Lecarpentier Manjeet K Bolla Qin Wang Jean Abraham Irene L Andrulis Hoda Anton-Culver Volker Arndt Paul L Auer Matthias W Beckmann Sabine Behrens Javier Benitez Marina Bermisheva Leslie Bernstein Carl Blomqvist Bram Boeckx Stig E Bojesen Bernardo Bonanni Anne-Lise Børresen-Dale Hiltrud Brauch Hermann Brenner Adam Brentnall Louise Brinton Per Broberg Ian W Brock Sara Y Brucker Barbara Burwinkel Carlos Caldas Trinidad Caldés Daniele Campa Federico Canzian Angel Carracedo Brian D Carter Jose E Castelao Jenny Chang-Claude Stephen J Chanock Georgia Chenevix-Trench Ting-Yuan David Cheng Suet-Feung Chin Christine L Clarke Emilie Cordina-Duverger Fergus J Couch David G Cox Angela Cox Simon S Cross Kamila Czene Mary B Daly Peter Devilee Janet A Dunn Alison M Dunning Lorraine Durcan Miriam Dwek Helena M Earl Arif B Ekici A Heather Eliassen Carolina Ellberg Christoph Engel Mikael Eriksson D Gareth Evans Jonine Figueroa Dieter Flesch-Janys Henrik Flyger Marike Gabrielson Manuela Gago-Dominguez Eva Galle Susan M Gapstur Montserrat García-Closas José A García-Sáenz Mia M Gaudet Angela George Vassilios Georgoulias Graham G Giles Gord Glendon David E Goldgar Anna González-Neira Grethe I Grenaker Alnæs Mervi Grip Pascal Guénel Lothar Haeberle Eric Hahnen Christopher A Haiman Niclas Håkansson Per Hall Ute Hamann Susan Hankinson Elaine F Harkness Patricia A Harrington Steven N Hart Jaana M Hartikainen Alexander Hein Peter Hillemanns Louise Hiller Bernd Holleczek Antoinette Hollestelle Maartje J Hooning Robert N Hoover John L Hopper Anthony Howell Guanmengqian Huang Keith Humphreys David J Hunter Wolfgang Janni Esther M John Michael E Jones Arja Jukkola-Vuorinen Audrey Jung Rudolf Kaaks Maria Kabisch Katarzyna Kaczmarek Michael J Kerin Sofia Khan Elza Khusnutdinova Johanna I Kiiski Cari M Kitahara Julia A Knight Yon-Dschun Ko Linetta B Koppert Veli-Matti Kosma Peter Kraft Vessela N Kristensen Ute Krüger Tabea Kühl Diether Lambrechts Loic Le Marchand Eunjung Lee Flavio Lejbkowicz Lian Li Annika Lindblom Sara Lindström Martha Linet Jolanta Lissowska Wing-Yee Lo Sibylle Loibl Jan Lubiński Michael P Lux Robert J MacInnis Melanie Maierthaler Tom Maishman Enes Makalic Arto Mannermaa Mehdi Manoochehri Siranoush Manoukian Sara Margolin Maria Elena Martinez Dimitrios Mavroudis Catriona McLean Alfons Meindl Pooja Middha Nicola Miller Roger L Milne Fernando Moreno Anna Marie Mulligan Claire Mulot Rami Nassir Susan L Neuhausen William T Newman Sune F Nielsen Børge G Nordestgaard Aaron Norman Håkan Olsson Nick Orr V Shane Pankratz Tjoung-Won Park-Simon Jose I A Perez Clara Pérez-Barrios Paolo Peterlongo Christos Petridis Mila Pinchev Karoliona Prajzendanc Ross Prentice Nadege Presneau Darya Prokofieva Katri Pylkäs Brigitte Rack Paolo Radice Dhanya Ramachandran Gadi Rennert Hedy S Rennert Valerie Rhenius Atocha Romero Rebecca Roylance Emmanouil Saloustros Elinor J Sawyer Daniel F Schmidt Rita K Schmutzler Andreas Schneeweiss Minouk J Schoemaker Fredrick Schumacher Lukas Schwentner Rodney J Scott Christopher Scott Caroline Seynaeve Mitul Shah Jacques Simard Ann Smeets Christof Sohn Melissa C Southey Anthony J Swerdlow Aline Talhouk Rulla M Tamimi William J Tapper Manuel R Teixeira Maria Tengström Mary Beth Terry Kathrin Thöne Rob A E M Tollenaar Ian Tomlinson Diana Torres Thérèse Truong Constance Turman Clare Turnbull Hans-Ulrich Ulmer Michael Untch Celine Vachon Christi J van Asperen Ans M W van den Ouweland Elke M van Veen Camilla Wendt Alice S Whittemore Walter Willett Robert Winqvist Alicja Wolk Xiaohong R Yang Yan Zhang Douglas F Easton Peter A Fasching Heli Nevanlinna Diana M Eccles Paul D P Pharoah Marjanka K Schmidt

Br J Cancer 2019 Feb 21. Epub 2019 Feb 21.

The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Division of Molecular Pathology, Amsterdam, The Netherlands.

Background: We examined the associations between germline variants and breast cancer mortality using a large meta-analysis of women of European ancestry.

Methods: Meta-analyses included summary estimates based on Cox models of twelve datasets using ~10.4 million variants for 96,661 women with breast cancer and 7697 events (breast cancer-specific deaths). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0393-xDOI Listing
February 2019

Defining and listing very rare cancers of paediatric age: consensus of the Joint Action on Rare Cancers in cooperation with the European Cooperative Study Group for Pediatric Rare Tumors.

Eur J Cancer 2019 Feb 19;110:120-126. Epub 2019 Feb 19.

Department of Epidemiological Research and Molecular Medicine, Evaluative Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy. Electronic address:

Although all tumours are rare in childhood, there are some particularly rare paediatric cancers which have not benefited from advances made by the international paediatric oncology network. To establish a shared definition and produce a list of these entities, the European Union Joint Action on Rare Cancers (JARC) promoted a consensus effort. The definition was based on the incidence rates estimated using the information network on rare cancers (RARECAREnet) database, pooling data from 94 population-based cancer registries and 27 countries. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2018.12.031DOI Listing
February 2019

Evaluation of antiemetic practices for prevention of chemotherapy-induced nausea and vomiting (CINV): results of a European oncology nurse survey.

Support Care Cancer 2019 Feb 19. Epub 2019 Feb 19.

Nursing Research Unit, University Hospital Halle (Saale), Halle, Germany.

Introduction: Preventing CINV is possible when guideline-recommended antiemetics are used. Because oncology nurses play a critical role in risk assessment and management of CINV, a survey of European nurses was conducted to evaluate antiemetic practices, assess awareness of and adherence to current guideline recommendations, and explore barriers to adherence.

Methods: From March 2016 to Feb 2017, 212 oncology nurses in 16 European countries completed a 20-question online survey. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00520-019-04697-1DOI Listing
February 2019

Optimisation of [C]-choline synthesis.

Contemp Oncol (Pozn) 2018 31;22(4):260-265. Epub 2018 Dec 31.

Department of Medical Physics, Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice Branch, Poland.

The importance of [C]-choline as a PET/CT marker has been extensively described, although its production presents considerable technical difficulties. The main ones are short half-lives and the occurrence of dimethylformamide (DMF) as a residual solvent. While the losses resulting from the radionuclide decay can be minimised by shortening the duration of the process, the best solution for reducing the content of DMF is its elimination from the reaction environment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5114/wo.2018.81751DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377417PMC
December 2018

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma.

Blood 2019 Feb 19. Epub 2019 Feb 19.

Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, United States;

Peripheral T-cell lymphoma (PTCL) is a group of complex clinicopathological entities, often associated with an aggressive clinical course. Angioimmunoblastic T-cell lymphoma (AITL) and PTCL-not otherwise specified (PTCL-NOS) are the two most frequent categories accounting for more than 50% of PTCLs. Gene expression profiling (GEP) defined molecular signatures for AITL and delineated biological and prognostic subgroups within PTCL-NOS (PTCL-GATA3 and PTCL-TBX21). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2018-09-872549DOI Listing
February 2019

Robot-assisted versus open cystectomy in the RAZOR trial.

Lancet 2019 Feb 14;393(10172):645. Epub 2019 Feb 14.

Department of Urology, Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, 20132 Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(18)33006-XDOI Listing
February 2019

Data ambiguity and clinical decision making: A qualitative case study of the use of predictive information technologies in a personalized cancer clinical trial.

Health Informatics J 2019 Feb 19:1460458219827355. Epub 2019 Feb 19.

IEO, European Institute of Oncology, IRCCS, Milan, Italy.

Personalized medicine aims to tailor the treatment to the specific characteristics of the individual patient. In the process, physicians engage with multiple sources of data and information to decide on a personalized treatment. This article draws on a qualitative case study of a clinical trial testing a method for matching treatments for advanced cancer patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1460458219827355DOI Listing
February 2019

Joint reconstruction and classification of tumor cells and cell interactions in melanoma tissue sections with synthesized training data.

Int J Comput Assist Radiol Surg 2019 Feb 16. Epub 2019 Feb 16.

Institute for Numerical Simulation, University of Bonn, Bonn, Germany.

Purpose: Cancers are almost always diagnosed by morphologic features in tissue sections. In this context, machine learning tools provide new opportunities to describe tumor immune cell interactions within the tumor microenvironment and thus provide phenotypic information that might be predictive for the response to immunotherapy.

Methods: We develop a machine learning approach using variational networks for joint image denoising and classification of tissue sections for melanoma, which is an established model tumor for immuno-oncology research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11548-019-01919-zDOI Listing
February 2019

Current and Potential Approaches for Defining Disease Signatures: a Systematic Review.

J Mol Neurosci 2019 Feb 18. Epub 2019 Feb 18.

Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.

Identifying disease signatures in order to facilitate accurate diagnosis/treatment has been the focus of research efforts in the last decade. However, the term "disease signature" has not been properly defined, resulting in inconsistencies between studies, as well as limited ability to fully utilize the tools/information available in the evolving field of healthcare big data. Research was conducted according to the Preferred Reporting Items for Systematic Review and Meta-analyses (PRISMA) guidelines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12031-019-01269-0DOI Listing
February 2019

Two-Year Follow-Up of a Multi-centre Randomized Controlled Trial to Study Effectiveness of a Hospital-Based Work Support Intervention for Cancer Patients.

J Occup Rehabil 2019 Feb 16. Epub 2019 Feb 16.

Coronel Institute of Occupational Health, Amsterdam Public Health Research Institute, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, The Netherlands.

Purpose Purpose is to: (1) study effectiveness of the hospital-based work support intervention for cancer patients at two years of follow-up compared to usual care and (2) identify which early factors predict time to return-to-work (RTW). Methods In this multi-center randomised controlled trial (RCT), 106 (self-)employed cancer patients were randomized to an intervention group or control group and provided 2 years of follow-up data. The intervention group received patient education and work-related support at the hospital. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10926-019-09831-8DOI Listing
February 2019

Multi-omic measurements of heterogeneity in HeLa cells across laboratories.

Nat Biotechnol 2019 Feb 18. Epub 2019 Feb 18.

Department of Biology, Institute of Molecular Systems Biology, ETH Zurich, Zurich, Switzerland.

Reproducibility in research can be compromised by both biological and technical variation, but most of the focus is on removing the latter. Here we investigate the effects of biological variation in HeLa cell lines using a systems-wide approach. We determine the degree of molecular and phenotypic variability across 14 stock HeLa samples from 13 international laboratories. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41587-019-0037-y
Publisher Site
http://dx.doi.org/10.1038/s41587-019-0037-yDOI Listing
February 2019
1 Read

Protein-coding variants implicate novel genes related to lipid homeostasis contributing to body-fat distribution.

Authors:
Anne E Justice Tugce Karaderi Heather M Highland Kristin L Young Mariaelisa Graff Yingchang Lu Valérie Turcot Paul L Auer Rebecca S Fine Xiuqing Guo Claudia Schurmann Adelheid Lempradl Eirini Marouli Anubha Mahajan Thomas W Winkler Adam E Locke Carolina Medina-Gomez Tõnu Esko Sailaja Vedantam Ayush Giri Ken Sin Lo Tamuno Alfred Poorva Mudgal Maggie C Y Ng Nancy L Heard-Costa Mary F Feitosa Alisa K Manning Sara M Willems Suthesh Sivapalaratnam Goncalo Abecasis Dewan S Alam Matthew Allison Philippe Amouyel Zorayr Arzumanyan Beverley Balkau Lisa Bastarache Sven Bergmann Lawrence F Bielak Matthias Blüher Michael Boehnke Heiner Boeing Eric Boerwinkle Carsten A Böger Jette Bork-Jensen Erwin P Bottinger Donald W Bowden Ivan Brandslund Linda Broer Amber A Burt Adam S Butterworth Mark J Caulfield Giancarlo Cesana John C Chambers Daniel I Chasman Yii-Der Ida Chen Rajiv Chowdhury Cramer Christensen Audrey Y Chu Francis S Collins James P Cook Amanda J Cox David S Crosslin John Danesh Paul I W de Bakker Simon de Denus Renée de Mutsert George Dedoussis Ellen W Demerath Joe G Dennis Josh C Denny Emanuele Di Angelantonio Marcus Dörr Fotios Drenos Marie-Pierre Dubé Alison M Dunning Douglas F Easton Paul Elliott Evangelos Evangelou Aliki-Eleni Farmaki Shuang Feng Ele Ferrannini Jean Ferrieres Jose C Florez Myriam Fornage Caroline S Fox Paul W Franks Nele Friedrich Wei Gan Ilaria Gandin Paolo Gasparini Vilmantas Giedraitis Giorgia Girotto Mathias Gorski Harald Grallert Niels Grarup Megan L Grove Stefan Gustafsson Jeff Haessler Torben Hansen Andrew T Hattersley Caroline Hayward Iris M Heid Oddgeir L Holmen G Kees Hovingh Joanna M M Howson Yao Hu Yi-Jen Hung Kristian Hveem M Arfan Ikram Erik Ingelsson Anne U Jackson Gail P Jarvik Yucheng Jia Torben Jørgensen Pekka Jousilahti Johanne M Justesen Bratati Kahali Maria Karaleftheri Sharon L R Kardia Fredrik Karpe Frank Kee Hidetoshi Kitajima Pirjo Komulainen Jaspal S Kooner Peter Kovacs Bernhard K Krämer Kari Kuulasmaa Johanna Kuusisto Markku Laakso Timo A Lakka David Lamparter Leslie A Lange Claudia Langenberg Eric B Larson Nanette R Lee Wen-Jane Lee Terho Lehtimäki Cora E Lewis Huaixing Li Jin Li Ruifang Li-Gao Li-An Lin Xu Lin Lars Lind Jaana Lindström Allan Linneberg Ching-Ti Liu Dajiang J Liu Jian'an Luan Leo-Pekka Lyytikäinen Stuart MacGregor Reedik Mägi Satu Männistö Gaëlle Marenne Jonathan Marten Nicholas G D Masca Mark I McCarthy Karina Meidtner Evelin Mihailov Leena Moilanen Marie Moitry Dennis O Mook-Kanamori Anna Morgan Andrew P Morris Martina Müller-Nurasyid Patricia B Munroe Narisu Narisu Christopher P Nelson Matt Neville Ioanna Ntalla Jeffrey R O'Connell Katharine R Owen Oluf Pedersen Gina M Peloso Craig E Pennell Markus Perola James A Perry John R B Perry Tune H Pers Ailith Ewing Ozren Polasek Olli T Raitakari Asif Rasheed Chelsea K Raulerson Rainer Rauramaa Dermot F Reilly Alex P Reiner Paul M Ridker Manuel A Rivas Neil R Robertson Antonietta Robino Igor Rudan Katherine S Ruth Danish Saleheen Veikko Salomaa Nilesh J Samani Pamela J Schreiner Matthias B Schulze Robert A Scott Marcelo Segura-Lepe Xueling Sim Andrew J Slater Kerrin S Small Blair H Smith Jennifer A Smith Lorraine Southam Timothy D Spector Elizabeth K Speliotes Kari Stefansson Valgerdur Steinthorsdottir Kathleen E Stirrups Konstantin Strauch Heather M Stringham Michael Stumvoll Liang Sun Praveen Surendran Karin M A Swart Jean-Claude Tardif Kent D Taylor Alexander Teumer Deborah J Thompson Gudmar Thorleifsson Unnur Thorsteinsdottir Betina H Thuesen Anke Tönjes Mina Torres Emmanouil Tsafantakis Jaakko Tuomilehto André G Uitterlinden Matti Uusitupa Cornelia M van Duijn Mauno Vanhala Rohit Varma Sita H Vermeulen Henrik Vestergaard Veronique Vitart Thomas F Vogt Dragana Vuckovic Lynne E Wagenknecht Mark Walker Lars Wallentin Feijie Wang Carol A Wang Shuai Wang Nicholas J Wareham Helen R Warren Dawn M Waterworth Jennifer Wessel Harvey D White Cristen J Willer James G Wilson Andrew R Wood Ying Wu Hanieh Yaghootkar Jie Yao Laura M Yerges-Armstrong Robin Young Eleftheria Zeggini Xiaowei Zhan Weihua Zhang Jing Hua Zhao Wei Zhao He Zheng Wei Zhou M Carola Zillikens Fernando Rivadeneira Ingrid B Borecki J Andrew Pospisilik Panos Deloukas Timothy M Frayling Guillaume Lettre Karen L Mohlke Jerome I Rotter Zoltán Kutalik Joel N Hirschhorn L Adrienne Cupples Ruth J F Loos Kari E North Cecilia M Lindgren

Nat Genet 2019 Feb 18. Epub 2019 Feb 18.

Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK.

Body-fat distribution is a risk factor for adverse cardiovascular health consequences. We analyzed the association of body-fat distribution, assessed by waist-to-hip ratio adjusted for body mass index, with 228,985 predicted coding and splice site variants available on exome arrays in up to 344,369 individuals from five major ancestries (discovery) and 132,177 European-ancestry individuals (validation). We identified 15 common (minor allele frequency, MAF ≥5%) and nine low-frequency or rare (MAF <5%) coding novel variants. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41588-018-0334-2DOI Listing
February 2019
29.352 Impact Factor

The European Society for Immunodeficiencies (ESID) Registry Working Definitions for the Clinical Diagnosis of Inborn Errors of Immunity.

J Allergy Clin Immunol Pract 2019 Feb 15. Epub 2019 Feb 15.

Institute for Immunodeficiency, Center for Chronic Immunodeficiency (CCI), Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany; Center for Pediatrics and Adolescent Medicine, Medical Center, Faculty of Medicine, University of Freiburg, Germany. Electronic address:

Patient registries are instrumental for clinical research in rare diseases. They help to achieve a sufficient sample size for epidemiological and clinical research and to assess the feasibility of clinical trials. The European Society for Immunodeficiencies (ESID) registry currently comprises information on >25,000 patients with inborn errors of immunity (IEI). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaip.2019.02.004DOI Listing
February 2019

Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.

Fundam Clin Pharmacol 2019 Feb 18. Epub 2019 Feb 18.

King's College London, Translational Oncology and Urology Research, London, United Kingdom.

One of the more recently investigated adverse long-term side effects of gonadotropin-releasing hormone (GnRH) agonists for prostate cancer (PCa) is cardiovascular disease (CVD). Studies suggest lower risk of CVD following GnRH antagonists (degarelix) than GnRH agonists. This protocol describes precise codes used to extract variables from five European databases for a study that compares risk of CVD following GnRH agonists and antagonists for PCa. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/fcp.12454DOI Listing
February 2019

Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update.

J Thorac Dis 2019 Jan;11(Suppl 1):S25-S36

Department of Biochemistry, Unit of Pharmacogenetics and Molecular Oncology, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France.

Immunotherapy represents one of the most promising therapeutic approaches in lung cancer, however 50% of lung cancer patients will not respond to this treatment, while others will have transitory or durable responses. Because side effects may be life threatening and treatment costs remain very high, the identification of predictive markers is mandatory and actually extensively studied. Factors that determine response to immune checkpoint inhibitors (ICI) are numerous including tumor microenvironment, immune tumor infiltrates, expression of immune checkpoint proteins (PD-1/PD-L1), gene expression signatures and molecular tumor profiles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/jtd.2018.12.48DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353739PMC
January 2019

Zinc deficiency in patients with chronic pancreatitis.

World J Gastroenterol 2019 Feb;25(5):600-607

Department for Digestive Diseases, Karolinska University Hospital, Stockholm 14186, Sweden.

Background: Zinc is a key element in numerous proteins and plays an important role in essential cell functions such as defense against free radicals and DNA damage repair. Chronic pancreatitis (CP) is a chronic inflammation with progressive fibrosis of pancreas ultimately resulting in pancreatic exocrine insufficiency (PEI), which is associated with malnutrition. Studies analyzing zinc levels in patients with CP are sparse and lead to conflicting results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3748/wjg.v25.i5.600DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6371007PMC
February 2019

Management of Urinary Retention in Patients with Benign Prostatic Obstruction: A Systematic Review and Meta-analysis.

Eur Urol 2019 Feb 14. Epub 2019 Feb 14.

Department of Urology, University General Hospital of Heraklion, University of Crete Medical School, Heraklion, Crete, Greece. Electronic address:

Context: Practice patterns for the management of urinary retention (UR) secondary to benign prostatic obstruction (BPO; UR/BPO) vary widely and remain unstandardized.

Objective: To review the evidence for managing patients with UR/BPO with pharmacological and nonpharmacological treatments included in the European Association of Urology guidelines on non-neurogenic male lower urinary tract symptoms.

Evidence Acquisition: Search was conducted up to April 22, 2018, using CENTRAL, MEDLINE, Embase, ClinicalTrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.01.046DOI Listing
February 2019

Lung Cancer App (LuCApp) study protocol: a randomised controlled trial to evaluate a mobile supportive care app for patients with metastatic lung cancer.

BMJ Open 2019 Feb 15;9(2):e025483. Epub 2019 Feb 15.

Centre for Research in Health and Social Care Management (CERGAS), SDA Bocconi, Milano, Italy.

Introduction: Mobile health technologies may enhance patient empowerment and data integration along the whole care continuum. However, these interventions pose relatively new regulatory, organisational and technological challenges that limit appropriate evaluation. Lung Cancer App (LuCApp) is a mobile application developed by researchers and clinicians to promote real-time monitoring and management of patients' symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/bmjopen-2018-025483DOI Listing
February 2019
1 Read

Impact of gene-specific germline pathogenic variants on presentation of endometrial cancer in Lynch syndrome.

Int J Gynecol Cancer 2019 Feb 16. Epub 2019 Feb 16.

Department of Gynecologic Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milano, Italy.

Objective: Lynch syndrome is a risk factor for developing endometrial carcinoma. Our aim was to evaluate the impact of gene-specific germline pathogenic variants on clinical features of patients affected by endometrial cancer.

Methods: Patients with a diagnosis of endometrial cancer and with a germline pathogenic variant in mismatch repair genes were reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/ijgc-2019-000277DOI Listing
February 2019

ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.

Eur J Cancer 2019 Feb 14;110:74-85. Epub 2019 Feb 14.

Department of Clinical Research, Gustave Roussy, Paris-Sud University, Paris, France.

Paediatric Strategy Forums have been created by the multistakeholder organisation, ACCELERATE, and the European Medicines Agency to facilitate dialogue between all relevant stakeholders and suggest strategies in critical areas of paediatric oncology drug development. As there are many medicines being developed for B-cell malignancies in adults but comparatively few in children with these malignancies, a Paediatric Strategy Forum was held to discuss the best approach to develop these products for children. It was concluded that as current frontline therapy is highly successful, despite associated acute toxicity, de-escalation of this or substitution of presently used drugs with new medicines can only be undertaken when there is an effective salvage regimen, which is currently not available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2019.01.013DOI Listing
February 2019
1 Read

Essential Research Priorities in Renal Cancer: A Modified Delphi Consensus Statement.

Eur Urol Focus 2019 Feb 13. Epub 2019 Feb 13.

Department of Surgery, University of Cambridge, Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK. Electronic address:

Background: Identification of clear and focused research priorities is crucial to drive research forward.

Objective: To identify research priorities in renal cell carcinoma (RCC) through a multidisciplinary collaboration between clinicians, researchers, and patients.

Design, Setting, And Participants: In phase I, 44 RCC experts provided 24 literature reviews within their field, summarising research gaps (RGs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.01.014DOI Listing
February 2019
1 Read

THE SMALL FATAL CHOROIDAL MELANOMA STUDY A Survey by the European Ophthalmic Oncology Group.

Am J Ophthalmol 2019 Feb 14. Epub 2019 Feb 14.

Ocular Oncology Service, Department of Ophthalmology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.

Purpose: To determine the size at which choroidal melanomas can metastasize and to report the characteristics of small fatal choroidal melanomas (SFCM).

Design: Retrospective case series.

Methods: Ten ocular oncology services submitted 45 patients with a choroidal melanoma 3 mm or less in thickness and 9 mm or less in largest basal diameter (LBD), when treated, who developed metastases. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00029394193006
Publisher Site
http://dx.doi.org/10.1016/j.ajo.2019.01.031DOI Listing
February 2019
5 Reads

Ready for Germany's revised radiation rules?

Authors:
Manfred Kurz

Crit Rev Oncol Hematol 2019 Feb 6;134:82-86. Epub 2018 Dec 6.

Regulatory Strategy Department - H. Lundbeck A/S, Ottiliavej 9, 2500 Valby, Denmark. Electronic address:

The assessment of the benefit-risk ratio of investigational medicinal products (IMPs) and the approval of clinical trial applications (CTAs) conducted in the European Union (EU) is a remit of national competent authorities (NCAs) of the 28 member states. The aim of this article is to shed light on clinical studies for oncology drugs carried out in Germany which involve diagnostic radiation tests. The authorisation process surrounding diagnostic radiology accompanying clinical investigations and used for measuring IMP related treatment effects is not well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.11.012DOI Listing
February 2019

The risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysis.

Crit Rev Oncol Hematol 2019 Feb 9;134:72-81. Epub 2019 Jan 9.

Cancer Risk Factors and Lifestyle Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy. Electronic address:

We conducted a meta-analysis of studies reporting on the risk of extra-ovarian malignancies among women with endometriosis. Summary relative risk (SRR) and 95% confidence intervals (CI) were calculated through random effect models. We explored causes of between-studies heterogeneity and assessed the presence of publication bias. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.12.009DOI Listing
February 2019
2 Reads

The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper.

Crit Rev Oncol Hematol 2019 Feb 19;134:39-45. Epub 2018 Dec 19.

Department of Tumor Biology, Center of Experimental Medicine, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.

Background: The heterogeneity of metastatic breast cancer (MBC) necessitates novel biomarkers allowing stratification of patients for treatment selection and drug development. We propose to use the prognostic utility of circulating tumor cells (CTCs) for stratification of patients with stage IV disease.

Methods: In a retrospective, pooled analysis of individual patient data from 18 cohorts, including 2436 MBC patients, a CTC threshold of 5 cells per 7. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2018.12.004DOI Listing
February 2019
1 Read

Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients.

Cancer Epidemiol 2019 Feb 13;59:135-142. Epub 2019 Feb 13.

Cancer Prognostics and Health Outcomes Unit, University of Montreal Health Center, Montreal, Québec, Canada; Division of Urology, University of Montreal Hospital Center (CHUM), Montreal, Quebec, Canada.

Background: We analysed contemporary pelvic lymph node dissection (PLND) trend during radical cystectomy (RC) for urothelial carcinoma of urinary bladder (UCUB), as well as PLND association with cancer specific mortality (CSM) and complications after stratification according to octogenarian vs. younger age.

Materials And Methods: Within the SEER and NIS databases, respectively 10,427 (T2 and T3 stages) and 19,203 (all T-stages) RC patients (2004-2015) for UCUB were identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2019.02.002DOI Listing
February 2019
1 Read

Just choice: a Danielsian analysis of the aims and scope of prenatal screening for fetal abnormalities.

Med Health Care Philos 2019 Feb 15. Epub 2019 Feb 15.

Department of Health, Ethics and Society, GROW School for Oncology and Developmental Biology, Faculty of Health, Medicine and Life Sciences, Maastricht University, 6200 MD, Maastricht, The Netherlands.

Developments in Non-Invasive Prenatal Testing (NIPT) and cell-free fetal DNA analysis raise the possibility that antenatal services may soon be able to support couples in non-invasively testing for, and diagnosing, an unprecedented range of genetic disorders and traits coded within their unborn child's genome. Inevitably, this has prompted debate within the bioethics literature about what screening options should be offered to couples for the purpose of reproductive choice. In relation to this problem, the European Society of Human Genetics (ESHG) and American Society of Human Genetics (ASHG) tentatively recommend that any expansion of this type of screening, as facilitated by NIPT, should be limited to serious congenital and childhood disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11019-019-09888-5DOI Listing
February 2019
1 Read

The Phylogeographic Diversity of EBV and Admixed Ancestry in the Americas⁻Another Model of Disrupted Human-Pathogen Co-Evolution.

Cancers (Basel) 2019 Feb 14;11(2). Epub 2019 Feb 14.

Advanced Center for Chronic Diseases (ACCDiS), Pontificia Universidad Catolica de Chile, Santiago 8330034, Chile.

Epstein-Barr virus (EBV) is an etiological agent for gastric cancer with significant worldwide variations. Molecular characterizations of EBV have shown phylogeographical variations among healthy populations and in EBV-associated diseases, particularly the cosegregated BamHI-I fragment and XhoI restriction site of exon 1 of the gene. In the Americas, both cosegregated variants are present in EBV carriers, which aligns with the history of Asian and European human migration to this continent. Read More

View Article

Download full-text PDF

Source
http://www.mdpi.com/2072-6694/11/2/217
Publisher Site
http://dx.doi.org/10.3390/cancers11020217DOI Listing
February 2019
2 Reads

Peptide vaccines in early breast cancer.

Breast 2019 Feb 7;44:128-134. Epub 2019 Feb 7.

IEO, European Institute of Oncology IRCCS, Milan Italy; University of Milan, Italy. Electronic address:

The immune system plays a dual role of host-protecting and tumor-promoting, as elegantly expressed by the 'cancer immunoediting' hypothesis. Although breast cancer has not been traditionally considered to be immunogenic, recently there is accumulating and solid evidence on the association between immune system and breast cancer. To mount an effective anti-tumor response, host immunosurveillance must recognize tumor-specific epitopes, thus defining the antigenicity of a tumor. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S09609776193002
Publisher Site
http://dx.doi.org/10.1016/j.breast.2019.02.003DOI Listing
February 2019
2 Reads

Ten years of Genome Medicine.

Genome Med 2019 02 15;11(1). Epub 2019 Feb 15.

Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Auerbachstraße, 70376, Stuttgart, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13073-019-0618-xDOI Listing
February 2019

Extracellular Vesicles in Liver Diseases: Meeting Report from the International Liver Congress 2018.

Hepatol Commun 2019 Feb 2;3(2):305-315. Epub 2019 Jan 2.

Department of Oncology, Hematology and Rheumatology University Hospital Bonn Bonn Germany.

Extracellular vesicles (EVs) are small and heterogeneous membrane-bound structures released by cells and found in all biological fluids. They are effective intercellular communicators, acting on a number of close and/or distant target cells. EV cargo may reflect the cell of origin as well as the specific stress that induces their formation and release. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hep4.1300DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6357829PMC
February 2019

Critical Care Aspects of Gallstone Disease.

J Crit Care Med (Targu Mures) 2019 Jan 4;5(1):6-18. Epub 2019 Feb 4.

Department of Medicine, Division of Gastroenterology and Liver Diseases, Marion Bessin Liver Research Center, "Albert Einstein" College of Medicine, Bronx, NY 10461, USA.

Approximately twenty per cent of adults have gallstones making it one of the most prevalent gastrointestinal diseases in Western countries. About twenty per cent of gallstone patients requires medical, endoscopic, or surgical therapies such as cholecystectomy due to the onset of gallstone-related symptoms or gallstone-related complications. Thus, patients with symptomatic, uncomplicated or complicated gallstones, regardless of the type of stones, represent one of the largest patient categories admitted to European hospitals. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2478/jccm-2019-0003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6369569PMC
January 2019
1 Read

Synergistic antitumour activity of HDAC inhibitor SAHA and EGFR inhibitor gefitinib in head and neck cancer: a key role for ΔNp63α.

Br J Cancer 2019 Feb 15. Epub 2019 Feb 15.

Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Via Adamello 16, 20139, Milan, Italy.

Background: Epidermal growth factor receptor (EGFR) overexpression is associated with the development of head and neck cancer (HNC) and represents one of the main therapeutic targets for this disease. The use of EGFR inhibitors has limited efficacy due to their primary and acquired resistance, partially because of increased epithelial to mesenchymal transition (EMT). The HDAC inhibitor SAHA has been shown to revert EMT in different tumours, including HNC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41416-019-0394-9DOI Listing
February 2019

Intravital imaging of glioma border morphology reveals distinctive cellular dynamics and contribution to tumor cell invasion.

Sci Rep 2019 Feb 14;9(1):2054. Epub 2019 Feb 14.

Hubrecht Institute-KNAW & University Medical Center Utrecht, Uppsalalaan 8, 3584 CT, Utrecht, The Netherlands.

The pathogenesis of glioblastoma (GBM) is characterized by highly invasive behavior allowing dissemination and progression. A conclusive image of the invasive process is not available. The aim of this work was to study invasion dynamics in GBM using an innovative in vivo imaging approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41598-019-38625-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6375955PMC
February 2019

BCR-dependent lineage plasticity in mature B cells.

Science 2019 02;363(6428):748-753

Immune Regulation and Cancer, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125 Berlin, Germany.

B2 cells engage in classical antibody responses, whereas B1 cells are considered carriers of innate immunity, biased toward recognizing epitopes present on the surfaces of common pathogens and self antigens. To explore the role of B cell antigen receptor (BCR) specificity in driving B1 cell differentiation, we developed a transgenic system allowing us to change BCR specificity in B cells in an inducible and programmed manner. Mature B2 cells differentiated into bona fide B1 cells upon acquisition of a B1 cell-typical self-reactive BCR through a phase of proliferative expansion. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/science.aau8475DOI Listing
February 2019
1 Read

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Lancet Oncol 2019 Feb 11. Epub 2019 Feb 11.

Institut Gustave Roussy, Université Paris Sud, INSERM U981, Villejuif, France.

Background: HER2-positive breast cancers usually contain large amounts of T-cell infiltrate. We hypothesised that trastuzumab resistance in HER2-positive breast cancer could be mediated by immune mechanisms. We assessed the safety and anti-tumour activity of pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, added to trastuzumab in trastuzumab-resistant, advanced HER2-positive breast cancer. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S14702045183081
Publisher Site
http://dx.doi.org/10.1016/S1470-2045(18)30812-XDOI Listing
February 2019
3 Reads